A carregar...
Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience
Background Ibrutinib is a Bruton’s tyrosine kinase inhibitor, which is United States Food and Drug Administration (FDA)-approved for chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström’s macroglobulinemia. Ibrutinib is associated with atrial fibrillation and bleeding events. Our aim...
Na minha lista:
| Publicado no: | Cureus |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Cureus
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6063389/ https://ncbi.nlm.nih.gov/pubmed/30062075 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.2701 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|